We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

ERBA MANNHEIM

Erba Mannheim is an IVD solutions provider focused on improving health outcomes in developing nations. Originally fou... read more Featured Products: More products

Download Mobile App





Erba Mannheim Showcases New Launches at MEDICA 2019

By LabMedica International staff writers
Posted on 20 Nov 2019
Erba Mannheim (London, UK) showcased some exciting new launches and provided a preview of NEXUS, its future generation of hematology, chemistry and immunoassay systems, at the MEDICA 2019 International Trade Fair on November 18-21 in Düsseldorf, Germany. More...
MEDICA is the world's largest annual medical technology trade fair and provides the medical device industry with a central market for innovative products and systems that result in an important contribution to the efficiency and quality of patient care. The combination of product shows with international congresses, forums, as well as expert workshops, and the exchange of professional views make MEDICA a meeting point for international professionals from various fields in the medical sector.

Erba Mannheim is an emerging player in the global IVD market and offers innovative solutions for lab diagnostics. At MEDICA 2019, the company showcased some of its new launches, including its new EC90 electrolyte analyzer with maintenance-free electrodes in an all-in-one sensor cartridge that is aimed at labs of all sizes. The EC 90 directly measures Na+, Cl-, K+ and Ca2+ from whole blood, plasma, serum and pre-diluted urine using a sensor incorporating thick film technology. The ‘plug and play’ sensor cartridge is integrated into a new reagent pack capable of performing up to 3,000 samples, with a market leading on-board lifetime of three months. No maintenance or cleaning of the pack is required, and waste is self-contained. The EC 90 can analyze samples in 35 seconds, with a typical throughput of 90 samples/hour, and has 35µL and 70µL sample volume measuring modes. Results can be given with a resolution of 0.1mmol/L for Na+ and Cl-, 0.01mmol/L for K+ and Ca2+, and are reproducible with CV< 1%. Small and lightweight (337 x 273 x 422mm, <8kg), the EC 90 features an 8.5-inch color touchscreen display, LIS connectivity, automatic calibration, two USB ports, on-board 24 column thermal printer and a serial port.

Erba Mannheim also showcased the ELAN 30s, a new fully automated compact benchtop ELISA microstrip processor with easy-to-use software, including QC reports and the ability to perform six different tests simultaneously. ELAN 30s eliminates the need for a ELISA reader and washer, making it the ultimate automated solution for labs with small, medium and varied ELISA workloads.

Also on display at this year’s MEDICA was Erba Mannheim’s XL 200 fully automated random access clinical chemistry analyzer with a throughput of 200 tests/hour (photometric test) and 400 tests/hour with ISE (Na/K/Cl/Li). The XL 200 offers 30 position reagent tray with on-board cooling, convenient software and an extensive quality control menu.

At MEDICA 2019, Erba Mannheim provided a preview of its new NEXUS advanced automation range. NEXUS will provide labs with a modular solution designed to deliver mid-scale, advanced-automation across immunology, clinical chemistry and hematology, using a powerful array of technology such as advanced imaging, artificial intelligence, thick film ISE and high sensitivity magnetic beads for CLIA analysis.

Related Links:
Erba Mannheim


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Manual Pipetting Aid
Pipette Controllers macro
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.